- Lobbying
- muscular AND dystrophy
Lobbying Arrangements Results for 'Muscular Dystrophy'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details 21st Century Cures/Biomedical Innovations; PDUFA VI; Appropriations Bill/Report Language, Orphan Drug Act Re-authorization, Newborn Screening Saves Lives Act Re-authorization Appropriations Congres... |
Parent Project Muscular Dystrophy
|
in-house lobbying | |||
Details Funding for CDC, NIH, HHS, and FDA related to muscular dystrophy and other health research Reauthorization for the Muscular Dystrophy Care Act Funding for CDC, NIH, HHS, and FDA related to Muscular... |
Parent Project Muscular Dystrophy
|
Cornerstone Government Affairs, LLC | |||
Details NIH, CDC, FDA, and DOD issues and funding relating to muscular dystrophy research and programs. |
Parent Project Muscular Dystrophy
|
Faegre Drinker Biddle & Reath LLP | |||
Details NIH, CDC, and FDA issues relating to muscular dystrophy |
PARENT PROJECT MUSCULAR DYSTROPHY
|
Faegre Baker Daniels Consulting | |||
Details FDA issues. Seeking accelerated approval for breakthrough medical treatments to treat Duchenne Muscular Dystrophy |
The Jett Foundation
|
O'NEILL AND ASSOCIATES | |||
Details Research funding for Duchenne Muscular Dystrophy |
Foundation to Eradicate Duchenne
|
Cornerstone Government Affairs, Inc. | |||
Details FY13 and FY14 Army Medical research funding. Specifically funding within the Congressional Directed Medical Research Program. |
Foundation to Eradicate Duchenne, Inc.
|
NorthPoint Consulting, LLC | |||
Details Defense Health Program and Army Medical research and development funding. |
Foundation to Eradicate Duchenne, Inc.
|
NORTHPOINT STRATEGIES, LLC | |||
Details Health care issues affecting individuals with neuromuscular disease |
Muscular Dystrophy Association, Inc.
|
KING & SPALDING LLP | |||
Details Implementation of the accelerated approval provision of FDASIA as it pertains to treatments applicable for rare, deadly childhood diseases |
Team Joseph
|
WINNING STRATEGIES WASHINGTON | |||
Details Implementation of the accelerated approval provision of FDASIA as it pertains to treatments applicable for rare, deadly childhood diseases |
Charley's Fund
|
WINNING STRATEGIES WASHINGTON | |||
Details Advocated for the protection of the Medicaid program to the White House and Congress Supported enhanced funding for NCATS Supported the nomination of Duchenne muscular dystrophy in front of HRSAs... |
Muscular Dystrophy Association, Inc.
|
in-house lobbying | |||
Details Federal budget issues IRA implementation, innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program... |
Sarepta Therapeutics
|
TARPLIN, DOWNS & YOUNG, LLC |